Geoff Farrell, Professor of Hepatic Medicine, Director of Gastroenterology, The Canberra Hospital, Australia
Geoffrey Farrell graduated MB BS from the University of Tasmania in 1970, and trained in gastroenterology and hepatology at the Royal Prince Alfred and Royal Brisbane Hospitals, the latter with Lawrie Powell with whom he completed an MD on hepatic drug metabolism. He was awarded an NHMRC CJ Martin Fellowship to conduct post-doctoral research in UCSF, and in 1980 returned to Sydney to establish a Liver Research Group at Westmead Hospital. He was promoted to a personal chair in 1993, then accepted the Storr Chair in Hepatic Medicine. He remained Director of the Storr Liver Unit until Jan 2006, when he accepted the position as Professor of Hepatic Medicine with ANU Medical School and Director of Gastroenterology and Hepatology at The Canberra Hospital. He has held many leadership roles in medical research, gastroenterology, editorial boards, and academic medicine, including Editor-in-Chief of Journal of Gastroenterology and Hepatology since November 2006.
Geoff Farrell's research interests are in non-alcoholic steatohepatitis, viral hepatitis, drug-induced liver injury, and liver regeneration. He has published 3 books, including the first on non-alcoholic fatty liver disease, and written more than 180 scientific papers and 100 reviews/chapters and editorials in the fields of hepatology and biochemical pharmacology. His work is very highly cited, with an H-index of 50, more than 20 articles cited >100 times, average citation 32 per paper, and 15 articles being the subject of editorials in major medical journals. He is CIA on an NHMRC Program Grant to study the molecular and cellular basis of liver disease, and has recently held a Centre for Clinical Research Excellence Program grant to improve outcomes for patients with liver disease.
Arthur McCullough, Department Chair of Gastroenterology and Hepatology, Cleveland Clinic, USA
Arthur McCullough, MD, is Department Chair of Gastroenterology and Hepatology and a Staff Physician in the Department of Pathobiology and Transplantation Center at Cleveland Clinic. He was appointed in 2006. He attended medical school at SUNY Health Science Center at University Hospital of Syracuse, N.Y. He completed his internship and residency at Cleveland Clinic and a fellowship at Mayo Clinic in Rochester, Minn.
He is one of the most senior hepatologists in the United States and is the current President of the American Association for the Study of Liver Diseases. Other significant achievements are: Best Doctor's in America: "Midwest Region" annually from 1996-2008; Chair of the NIH-funded Clinical Research Network on Fatty Liver Disease (federal funding); NIH Grant on Omega 3 Fatty Acids in Diabetes (federal funding); New Novel Agents for Hepatitis C Patients who failed to respond to previous therapy (non-federal funding)
Christopher Day, Pro-Vice-Chancellor for the Faculty of Medical Sciences, Professor of Liver Medicine and Consultant Hepatologist, School of Clinical Medical Sciences, Newcastle University, UK
Chris Day qualified from Cambridge University in 1983 and subsequently trained in General Medicine and Hepatology at Newcastle, becoming Consultant Hepatologist in the Liver Unit at Newcastle’s Freeman Hospital in 1994 and Professor of Liver Medicine at University of Newcastle University in 2000. He was formerly Head of the School of Clinical Medical Sciences at the University and since April 2008 has been Pro-Vice-Chancellor of the Faculty of Medical Sciences. Professor Day's research interests focus largely on fatty liver disease related both to obesity and to alcohol, with additional interests in drug-induced liver injury and liver fibrosis. His work has been funded by the MRC and the Wellcome Trust and he is a former MRC Clinical Training Fellow and Clinician Scientist Fellow. In 1999 he was the Goulstonian Lecturer of the Royal College of Physicians and in 2000 was awarded the research gold medal of the British Society of Gastroenterology. He is a Fellow and Councillor of the Academy of Medical Sciences, an Executive Member of the Medical Schools Council and an NIHR Senior Investigator. He is also Chief Editor of the Journal of Hepatology, and is on both the Populations and Systems Medicine Board and the Translational Stem Cell Research Committee of the Medical Research Council.
It will improve your diagnostic acumen for people with abnormal liver tests, advance your knowledge about this important subject and help with your specialist or undergraduate exams, and management of a common disorder.
It will be of particular use for those GI internists/residents who have an interest specifically in hepatology. It does not aim to be a specialist textbook, but a shorter, 250pp guide that provides key clinical information on each area of hepatology in an accessible form. Extracting relevant material from large reference textbooks can be very time consuming and for this reason, information in this handbook will be presented succinctly in a style suitable for quick reference and easy understanding.
The chief emphasis will be on the clinical assessment and management of these patients, and all the major areas of liver disease will be covered, from liver cirrhosis to viral hepatitis, to autoimmune liver failure.
Chapters will use a variety of structural features and colour coded boxes to increase the accessibility for residents. These include: key points/take-home points, case history, practice points and management algorithm/flow-charts. Each chapter will also contain sample multiple choice questions that the reader will be able to test themselves on.
Cytology of the Mediastinum and Gut is a useful and practical guide for cytological interpretation and differential diagnosis of lesions obtained by EUS-FNA of mediastinum and gut. All chapters are written by experts with many years of experience in the field and contain the cytology, immuno-profile, molecular profile, and ultrasound features of the masses described.
Dr. Douglas G. Adler has designed this unique reference, which offers expert advice, preferences, and opinions on tough clinical questions commonly associated with GI cancer. The unique Q&A format provides quick access to current information related to GI cancer with the simplicity of a conversation between two colleagues. Numerous images, diagrams, and references are included to enhance the text and to illustrate the treatment of GI cancer patients.
Curbside Consultation in GI Cancer for the Gastroenterologist: 49 Clinical Questions provides information basic enough for residents while also incorporating expert advice that even high-volume clinicians will appreciate. Gastroenterologists, fellows and residents in training, surgical attendings, and surgical residents will benefit from the user-friendly and casual format and the expert advice contained within.
Some of the questions that are answered:
• An 81-year-old man is found to have unresectable esophageal cancer and malignant dysphagia. Should he have a stent? A nasogastric feeding tube? A PEG tube?
• How is tumor-related bleeding from gastric cancers best approached?
• Do patients with pancreatic cancer and jaundice need to have an ERCP preoperatively?
• What is the role of ERCP and EUS in patients with suspected cholangiocarcinoma?
• Why are rectal cancers so different from colon cancers with regards to medical and surgical management?
Curbside Consultation in GI Cancer for the Gastroenterologist: 49 Clinical Questions illustrates how patients at different points in their treatment may go back and forth between specialists to receive coordination of care, and incorporates input from gastroenterologists, surgeons, radiologists, and oncologists. While providing up-to-date information, this book will help gastroenterologists to manage complex cancer-related issues and guide physicians through the maze of cancer-related treatments available.
Ideal for practicing gastroenterologists, gastroenterology fellows, surgeons, oncologists, residents, and medical students, Curbside Consultation in GI Cancer for the Gastroenterologist: 49 Clinical Questions is sure to benefit anyone caring for patients with gastrointestinal cancers.